Login / Signup

InflammamiR-146a and -155 Plasma Levels are Associated with Clinical Efficacy of Risankizumab Treatment in Psoriatic Patients: Pilot Study.

Diotallevi FedericoGiulia MatacchioneGiovanni Marco d'AgostinoHelena GioacchiniAnna CampanatiJacopo SabbatinelliFabiola OlivieriAnnamaria Offidani
Published in: Dermatology and therapy (2023)
Our results reinforce the notion that specific circulating miRNAs could have clinical relevance as diagnostic/prognostic biomarkers of psoriatic disease and suggest the potential relevance of these miRNAs as biomarkers of treatment response.
Keyphrases
  • rheumatoid arthritis
  • end stage renal disease
  • ejection fraction
  • ankylosing spondylitis
  • newly diagnosed
  • disease activity
  • chronic kidney disease
  • systemic lupus erythematosus
  • climate change
  • risk assessment